Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

A. Rizvi, Naiyer; Chul Cho, Byoung; Reinmuth, Niels; Hyeong Lee, Ki; Luft, Alexander; Ahn, Myung‐Ju; M. van den Heuvel, Michel; Cobo, Manuel; Vicente, David; Smolin, Alexey; Moiseyenko, Vladimir; Antonia, Scott; Le Moulec, Sylvestre; Robinet, G.; B. Natale, Ronald; Schneider, Jeffrey; A. Shepherd, Frances; Lucien Geater, Sarayut; B. Garon, Edward; S. Kim, Edward; B. Goldberg, Sarah; Nakagawa, Kazuhiko; Raja, Rajiv; W. Higgs, Brandon; Boothman, Anne-Marie; Zhao, Luping; Scheuring, Urban; K. Stockman, Paul; K. Chand, Vikram; Peters, Solange; the MYSTIC Investigators, for

doi:10.1001/jamaoncol.2020.0237

Public

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Published in JAMA Oncology • Apr 9, 2020

Authors:

Naiyer A. Rizvi

Byoung Chul Cho

Niels Reinmuth

Abstract

Importance: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small cell lung cancer. Objective: To compare durvalumab, wi...

Subject

Durvalumab

Tremelimumab

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!